BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioXcel Therapeutics (BTAI) PT Raised to $128 at Truist Securities
May 10, 2021 12:13 PM EDTTruist Securities analyst Robyn Karnauskas raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $128.00 (from $127.00) while maintaining a Buy rating.
The analyst commented, "Key 1Q21 takeaways: 1) commercial US prep on track for '501 key indications launching 1Q22; 2) '501 EU market may provide... More
BioXcel Therapeutics (BTAI) Reports Q1 Loss of $1.08/sh
May 10, 2021 7:17 AM EDTBioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.08), versus ($0.79) reported last year.
For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.
... More